You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
|
|---|---|
| Published in |
Lancet Oncology, January 2019
|
| DOI | 10.1016/s1470-2045(18)30765-4 |
| Pubmed ID | |
| Authors |
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Olivier Molinier, Florian Guisier, Thierry Urban, Catherine Ligeza-Poisson, David Planchard, Elodie Amour, Franck Morin, Denis Moro-Sibilot, Gérard Zalcman, French Cooperative Thoracic Intergroup, Didier DEBIEUVRE, Sandrine HIRET, Jacques CADRANEL, Séverine FRABOULET-MOREAU, Delphine CARMIER |
X Demographics
The data shown below were collected from the profiles of 107 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 18 | 17% |
| United States | 17 | 16% |
| Spain | 10 | 9% |
| France | 9 | 8% |
| Italy | 8 | 7% |
| Colombia | 2 | 2% |
| Belgium | 2 | 2% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| Other | 9 | 8% |
| Unknown | 30 | 28% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 72 | 67% |
| Practitioners (doctors, other healthcare professionals) | 21 | 20% |
| Scientists | 13 | 12% |
| Science communicators (journalists, bloggers, editors) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 244 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 244 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 12% |
| Other | 28 | 11% |
| Student > Ph. D. Student | 26 | 11% |
| Student > Master | 19 | 8% |
| Student > Bachelor | 19 | 8% |
| Other | 43 | 18% |
| Unknown | 79 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 85 | 35% |
| Biochemistry, Genetics and Molecular Biology | 15 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 5% |
| Nursing and Health Professions | 11 | 5% |
| Immunology and Microbiology | 6 | 2% |
| Other | 28 | 11% |
| Unknown | 86 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 81. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2022.
All research outputs
#533,495
of 25,837,817 outputs
Outputs from Lancet Oncology
#675
of 6,943 outputs
Outputs of similar age
#12,085
of 450,821 outputs
Outputs of similar age from Lancet Oncology
#18
of 131 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,943 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,821 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.